Let's grab coffee in
San Diego

Meet me at OCT SoCal to learn more about why biotech sponsors have been choosing PSI CRO for their pivotal Phase 2 and 3 trials for more than 25 years.
Jeremie Braun

Senior Director, Business Development
Mobile: (310) 614-9413
jeremie.braun@psi-cro.com

Finally – A truly global CRO suited for small to midsize biotech companies
We’re a privately held, global CRO that specializes in Phase 2 and 3 clinical trials in select indications, including oncology, hematology, and IBD. We recognize that site relationships are integral to the success of your study, and we have proactively cultivated these relationships for the last 25 years, with more than 2,600 top-performing sites around the world to improve patient enrollment and client trust. That’s one of the reasons 90% of our business is repeat and referral – we know the meaning of trust and reliability.

Discover more about our recent customer success stories and therapeutic experience below

PSI OVERVIEW
Our mission is to be the best CRO in the world as measured by our employees, clients, investigators, and vendors.
CASE STUDY
Delivering trials is what we do. It’s our expertise – it’s what we’re dedicated to, and it’s what our teams are built for.
ONCOLOGY
Running oncology studies globally. We plan and execute seamless clinical trials with novel study designs.
HEMATOLOGY
PSI is one, if not the only, CRO that has been engaged extensively in gene therapy trials by half a dozen biotech sponsors.
IBD
As the need for clinical trials in Crohn’s disease and ulcerative colitis grows, CRO collaboration matters more than ever.
RADIOPHARMACEUTICAL
For radiopharmaceutical clinical trials, cooperation and coordination on a global scale is a must.
MS
Consistent delivery on dozens of MS trials, expert knowledge of running placebo-controlled MS trials around the world.
ID
Predictable enrollment and deep connections to sites and staff. PSI is an antibiotic powerhouse.
RARE DISEASE
The challenges of rare disease research, a global approach. Predictability in rare disease clinical trials.

The PSI Advantage

PSI CRO has been named a 2022 CRO Leadership Award Champion in the categories of Compatibility, Quality, and Reliability across two respondent groups (Overall and Small Pharma). This is also the fourth year in a row in which PSI CRO received CRO Leadership Awards in all five categories, also including Expertise and Capabilities. The CRO Leadership Awards are presented by Life Sciences Leader and Clinical Leader based on research conducted by ISR reports. The awards recognize CROs that are voted by sponsors to meet or exceed expectations.
Consent(Required)